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Antibodya b s t r a c t
The experimental vaccine for bovine malignant catarrhal fever consists of viable attenuated alcelaphine
herpesvirus 1 (AlHV-1) derived‘ by extensive culture passage, combined with an oil-in-water adjuvant,
delivered intramuscularly. This immunisation strategy was over 80% effective in previous experimental
and field trials and protection appeared to be associated with induction of virus-neutralising antibodies.
Whether the vaccine virus is required to be viable at the point of immunisation and whether adjuvant is
required to induce the appropriate immune responses remains unclear. To address these issues two studies
wereperformed, firstly to analyse immune responses in thepresence andabsence of adjuvant and secondly,
to investigate immune responses to vaccines containing adjuvant plus viable or inactivated AlHV-1.
The first study showed that viable attenuated AlHV-1 in the absence of adjuvant induced virus-specific
antibodies but the titres of virus-neutralising antibodies were significantly lower than those induced by
vaccine containing viable virus and adjuvant, suggesting adjuvant was required for optimal responses. In
contrast, the second study found that the vaccine containing inactivated (>99.9%) AlHV-1 induced similar
levels of virus-neutralising antibody to the equivalent formulation containing viable AlHV-1.
Together these studies suggest that the MCF vaccine acts as an antigen depot for induction of immune
responses, requiring adjuvant and a suitable antigen source, which need not be viable virus. These obser-
vations may help in directing the development of alternative MCF vaccine formulations for distribution
in the absence of an extensive cold chain.
 2021 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Malignant catarrhal fever (MCF) is a usually-fatal lymphoprolif-
erative disease affecting a range of ungulates caused by members
of the Macavirus genus of gammaherpesviruses, particularly alcela-
phine herpesvirus 1 (AlHV-1) and ovine herpesvirus 2 (OvHV-2) [1–
3]. Animals that exhibit clinical signs of MCF seldom survive,
although there is evidence that sub-clinical infection may occur
[4,5]. AlHV-1 is carried asymptomatically by wildebeest but can be
transmitted to disease-susceptible ungulates causing significant
losses in areas of eastern and southern Africa where wildebeest
and livestock come into contact and also in zoological collectionsworldwide [1,2]. MCF does not appear to transmit horizontally
between affected animals, suggesting clinical disease occurs only
in dead-end hosts, but examples of vertical transmission in MCF
reservoir and susceptible species have been recorded [6–8]. OvHV-
2 is carried asymptomatically by sheep and sheep-associated (SA-)
MCF is a problem worldwide wherever reservoir and disease-
susceptible hosts cohabit. Globally,MCF has both economic and ani-
mal welfare impacts [2,9–12].
Alcelaphine herpesviruses 1 and 2 are the only Macaviruses that
can currently be propagated in culture [13,14], althoughAlHV-2was
considered non-pathogenic in cattle, leading to the preferential use
ofAlHV-1overOvHV-2 to study thepathogenesis and control ofMCF
[15–21]. Pathogenic AlHV-1 can be propagated in a cell-associated
form in bovine primary epithelial cells but after several passages
the virus becomes culture-adapted and releases cell-free virus into
the culture medium [22,23]. This culture adaptation is associated
with loss of virulence, such that the resultant virus is unable to cause
MCF when used to infect cattle and rabbits [23,24]. The loss of virus
pathogenicity is associated with genomic changes, including rear-
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allowed the development of a vaccine against AlHV-1 MCF [19].
The high passage AlHV-1 C500 virus is a stable attenuated virus
strain which, when formulated with Freunds’ complete and incom-
plete adjuvants in an intramuscular two-dose strategy, protected
cattle from an intranasal challengewith the pathogenic C500 parent
strain of AlHV-1 thatwas usually fatal in unvaccinated animals [19].
This live-attenuated vaccine, using the licensed oil-in-water adju-
vant Emulsigen (https://mvpadjuvants.com/wp-content/uploads/
2017/10/PHIB-17018-Adjuvants-Bulletin_Emulsigen.pdf), was
found to be safe and effective in experimental and field trials involv-
ing hundreds of cattle [4,20,21,25,26].
However, it remains unclear whether this vaccine requires the
presence (and replication) of viable virus to function optimally or
if it simply provides a source of virus antigen. Here we report the
results of experiments in which the attenuated AlHV-1 vaccine
strain was used to immunise cattle in the absence of adjuvant,
mixed with adjuvant at the point of immunisation or stored in
adjuvant until virus viability was reduced by over 99.9%. We show
that the attenuated AlHV-1 MCF vaccine requires an adjuvant to
induce optimal (virus neutralising) immune responses but the
virus need not be viable. These results are an important advance
in our characterisation of the vaccine formulation to allow its
uptake commercially, especially in the absence of a cold chain.2. Materials and methods
2.1. Animals
Groups of 6–8 disease-free and AlHV-1 seronegative male Ayr-
shire, Holstein or Friesian-Holstein cross Bos taurus calves of 3–
7 months of age were used in the experiments. All animals
recruited were housed at the Moredun Research Institute animal
accommodation for at least one week before the start of any proce-
dures to allow their health status to be evaluated and to allow
acclimatisation. Power calculations based on an estimated fre-
quency of disease of 80% in unvaccinated cattle and 10% in vacci-
nated cattle after experimental challenge; a false positive rate of
0.05; and power of 80% were used to derive the group sizes used.
All animal experiments were performed with the approval of the
Moredun Research Institute’s Animal Welfare and Ethical Review
Body (AWERB) in compliance with the UK ‘‘Animals (Scientific Pro-
cedures) Act 1986”, which included a statistical review of group
sizes. The experimental design submitted for ethical review
included a statement that animals would be monitored daily for
health and well-being and that any animal developing more than
mild clinical signs would be euthanased for welfare reasons. One
animal was withdrawn from study 2 (group 2A) before the second
immunisation due to respiratory disease; the data from all other
animals were included in the analysis.
Individual units - animals - were assigned to experimental
groups randomly, while ensuring an even distribution of animal
ages and source locations as follows: animals were sorted by birth
location and UK animal number and then were assigned to groups
A, B and C in order. The groups in each study had average ages that
differed by less than one week. Staff involved in animal care were
blinded to the group allocations at all stages in the studies, while
the scientists involved in sample/data analysis were not. No sub-
jective judgements were involved in the analysis of samples.2.2. Immunisation study design
Table 1 shows the details of the two vaccine studies performed.
In study 1, three groups of at least six calves were immunised with:
attenuated AlHV-1 mixed with 20% Emulsigen immediately before2
use (group 1A, n = 6); attenuated AlHV-1 without adjuvant (group
1B, n = 6); and culture medium only (group 1C, n = 7). Virus titre in
the inoculum was 106–107 50% tissue-culture-infectious dose
(TCID50)/ml. Animals were given two doses of the same vaccine
formulation as intramuscular (upper neck) inoculations on day 0
(d0) and d28 and were sampled for blood and nasal secretions
on d0, d14, d28, d47, d56 and d69. Blood plasma and nasal secre-
tions (NS) were analysed for virus-specific antibodies by ELISA,
while d0 and d69 samples were tested for virus-neutralising anti-
bodies, to qualitatively evaluate the antibody responses.
In study 2 (Table 1) three groups of 8 calves were immunised
with: attenuated AlHV-1 vaccine containing 20% Emulsigen (~107
TCID50/ml), formulated on the day of immunisation (group 2A);
identically constituted vaccine that had been stored at 4 C with
mixing for four weeks and whose AlHV-1 viable titre (~103
TCID50/ml at the point of vaccination) had been reduced by more
than 99.9% (group 2B); and medium containing 20% Emulsigen
(group 2C). As in study 1, the animals in each group received two
doses of the same vaccine formulation as intramuscular (upper
neck) inoculations on d0 and d28. One animal in group 2A was
euthanased for welfare reasons before the second immunisation.
Samples of blood and nasal secretions were taken on d0, d28 and
d56, and was concluded on day 56, four weeks after booster vacci-
nation, while the virus-specific antibody response remained high
(Table 1). Antibody responses were analysed by AlHV-1 specific
ELISA and by virus neutralisation assay (VNA), as for study 1, focus-
ing on a time point representing the peak of immune response
(d56).
2.3. Cells, viruses and adjuvants
The strains of AlHV-1 used for vaccination and challenge were
as described previously [19,25]. Briefly, the attenuated AlHV-1
C500 strain at passage >1000 was used as the source of virus for
immunisation. This cell-free virus was propagated in primary
bovine turbinate (BT) cells at low passage and virus-containing cul-
ture supernatants were clarified by centrifugation and stored at
80 C. Representative aliquots of attenuated AlHV-1 were titrated
by serial dilution on BT cells as described previously [19] and are
expressed as TCID50/ml.
Emulsigen (MVP Adjuvants, Phibro Animal Health, USA) is a
licensed oil-in-water adjuvant that has no ingredients of animal
origin. It contains micron-sized oil droplets with a high surface
area available for antigen coating and does not cause adverse reac-
tions at the injection site. Previous analysis of the attenuated AlHV-
1 virus in combination with this adjuvant showed that 20% Emul-
sigen did not significantly reduce the titre of the virus in the 24 h
after mixing and that the adjuvant was not toxic to BT cells [25] in
virus titrations.
2.4. Virus viability assays
Aliquots of a single stock of attenuated AlHV-1 C500 virus were
incubated at 4 C or 20 C in the presence or absence of 20% Emul-
sigen for periods of up to two months. Samples were mixed daily
by inversion. After incubation, the proportion of viable AlHV-1
remaining in each sample was assayed by virus titration (TCID50)
on BT cells by serial dilution as described [19]. The setting up of
each replicate set was organised to allow the virus titrations to
be performed together, enhancing the reliability of the assays.
2.5. Detection of AlHV-1 DNA
The presence of AlHV-1 DNA in immunised animals was
assayed in purified genomic DNA samples extracted from periph-
eral blood buffy coat cells by real-time PCR as described previously
Table 1
Details of vaccine studies.
Study *Group (n) $Prime (d0) Boost (d28) ySampling days (d) assays
1 1A (6) Viable AlHV-1 /20% Emulsigen Viable AlHV-1 /20% Emulsigen Blood and NS: d0, d14, d28, d47, d56, d69 ELISA, VNA
1B (6) Viable AlHV-1 Viable AlHV-1
1C (7) Medium only Medium only
2 2A (7) Viable AlHV-1 /20% Emulsigen Viable AlHV-1 /20% Emulsigen Blood and NS: d0, d28, d56 ELISA, VNA
2B (8) Inactivated AlHV-1 /20% Emulsigen Inactivated AlHV-1 /20% Emulsigen
2C (8) 20% Emulsigen 20% Emulsigen
* Group designations and numbers of animals per group (n). One animal was withdrawn from study 2 (group 2A) before boost due to respiratory disease.
$ Immunisations (each 1 mL, given intramuscularly in the upper neck as prime on day 0 (d0), boost on d28).
y Sampling days (d) are expressed as days after first immunisation; sample types as Blood (uncoagulated blood) and NS (nasal secretions).
 Assays performed are shown as ELISA (AlHV-1 ELISA) and VNA (AlHV-1 virus neutralisation assay).
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colour) real-time PCR analysis that simultaneously assayed for the
presence of AlHV-1 DNA and bovine genomic b-actin specific DNA
sequences (as control for the extraction and PCR processes) on an
ABI 7000 or 7500 sequence detection system (Applied Biosystems).2.6. Analysis of antibody responses to AlHV-1 by ELISA and virus
neutralising antibody test
To quantify the humoral antibody response in blood plasma and
themucosal antibody response in nasal secretions (NS), an antibody
ELISA, based on a detergent extract of attenuated AlHV-1, was used
as described previously [25]. Briefly, pairs of adjacent rows of 96-
well microtitre plates (Greiner, high protein binding) were coated
with 50 lL of 5 lg/mL virus-positive or virus-negative antigen in
0.1 M carbonate buffer, pH 9.6. Individual samples of blood plasma
or sterile-filtered nasal secretion fluid diluted in PBS were then
applied in duplicate to positive and negative antigen wells at a dilu-
tion optimised in previous experiments (1/200 for plasma, 1/50 for
NS). A similar dilution of an AlHV-1-positive plasma or NS pool
was included on each plate as a positive control and to ensure repro-
ducibility between assays. Known negative samples of plasma and
NS were included with each test sample series. Antibody bound in
each well was detected using 1:1000 dilution of rabbit anti-bovine
IgG-Horseradish Peroxidase conjugate (Sigma). The plates were
then washed and Sureblue TMB-peroxidase substrate (KPL) applied
for five minutes. The reaction was stopped by the addition of 0.1 M
HCl and the plates were read at 450 nm in a plate reader. ELISA val-
ues (difference between means of positive and negative antigen
wells for each sample dilution) were normalised between plates
by calculationof the sample-to-positive (s/p) ratio for each test sam-
ple, based on the positive control samples included on each plate, as
described previously [25].
The virus neutralisation assay (VNA) was based upon inhibition
of AlHV-1-induced cytopathic effect in BT cells by AlHV-1 virus
neutralising antibodies in dilutions of plasma or nasal secretion
fluid as described previously [19]. Assays were performed in 96
well tissue culture plates with BT cells at greater than 80% conflu-
ence. All assays used a high titre bovine anti-AlHV-1 serum as a
positive control and included non-specific toxicity control wells
containing sample and cells without virus. VNA titres were
expressed as <2 when no neutralisation was detected at the lowest
dilution that could be used (1:2 final).Fig. 1. Chart of AlHV-1 viability when stored in the absence or presence of
Emulsigen (20%) at 4 C or 20 C. Conditions of storage (virus or virus plus
Emulsigen) are indicated below each group of columns. Storage times were as
follows: 7 days, black columns; 14 days, dark grey columns; 28 days, light grey
columns; 63 days, white columns. Values below the detection limit of the assay (102
TCID50/ml) are shown at that level.2.7. Statistical analysis
After testing for normality, comparison of immune response
data was performed by T-test on log2-transformed VNA titre data
or directly on ELISA s/p ratios within Microsoft Excel. Statistical
significance was assumed at p < 0.05. Immune response data were
also subjected to the non-parametric Mann-Whitney U test using3
an online calculator (www.socscistatistics.com/tests/mannwhit-
ney/), which allowed data to be analysed without transformation.
3. Results
3.1. Analysis of AlHV-1 viability in the presence and absence of
adjuvant
Titration of attenuated AlHV-1 after combination with Emulsi-
gen in previous vaccine studies showed that mixing with adjuvant
led to a less than ten-fold reduction in titre during the first 24 h
and that 20% Emulsigen in culture medium was not toxic to BT
cells in the context of virus titration assays [25]. In order to study
longer-term vaccine virus stability when formulated with adju-
vant, aliquots of attenuated AlHV-1 were incubated in the presence
or absence of Emulsigen (20%) with daily mixing for up to two
months. The resulting titre data are summarised in Fig. 1 and pre-
sented in Supplementary Data, Table 1.
In the absence of adjuvant, storage at 4 C led to an approxi-
mately ten-fold loss in titre after one month, and a hundred-fold
reduction after two months. Incubation at 20 C led to a more rapid
loss of viability, with reductions of about 103-fold observed at both
one and two months. Inclusion of Emulsigen caused a rapid and
progressive loss of titre at both 4 C and 20 C, with virus titre
reduced to approximately 103 TCID50/ml after one month and to
undetectable levels (<102 TCID50/ml) after two months (Fig. 1).
3.2. Study 1: immune response to attenuated AlHV-1 in the presence
and absence of adjuvant
To determine whether the MCF vaccine required adjuvant for
optimal performance, the immune response induced by immunisa-
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tested in study 1. Plasma ELISA showed that AlHV-1-specific anti-
bodies were induced by both the adjuvant-containing (group 1A)
and adjuvant-free (group 1B) immunisations (Fig. 2A), while theFig. 2. Study 1; ELISA and VNA data. In panels A and B the mean s/p value for each
group was plotted against day of study for the respective samples as follows: group
1A (viable AlHV-1 mixed with 20% Emulsigen on the day of immunisation), dark
grey circles and solid lines; group 1B (viable AlHV-1 only), mid grey squares and
dashed lines; and group 1C (culture medium only), light grey triangles and dotted
lines. Variation within each group is indicated by vertical black bars representing
the sample standard deviation. Prime immunisation was on d0, boost on d28
(arrows). (A) Plasma ELISA time course; (B) nasal secretion (NS) ELISA time course.
T-test comparison of NS s/p values in group 1A and group 1B showed significant
differences at d47, d56 (**, p < 0.01) and at d69 (*, p < 0.05). (C) Virus-neutralising
assay (VNA) data. The d69 VNA titres assayed in blood plasma (plasma VNA, dark
grey circles) and nasal secretions (NS VNA, light grey circles) were plotted on a log2
scale by sample type and immunisation group as indicated beneath the figure.
Samples with identical values in the same group were plotted offset to each other.
Differences between groups 1A and 1B were considered significant (* p < 0.0005, T-
test; p < 0.01, Mann-Whitney U test).
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control group (1C) had no such response. In contrast, only group
1A developed NS ELISA s/p values that were significantly higher
than the control group (1C) (Fig. 2B). In the adjuvant-vaccine group
(1A), the virus-specific antibody response remained low (median
and range <0.1) until after the booster immunisation at d28 and
peaked about 4 weeks later when s/p values rose to medians of
0.4–0.6 in plasma (range 0.6–1.0) and 0.2–0.4 in NS (range 0.4–
0.6) on d47, d56 and d69 (Fig. 2A, B). In contrast, the group immu-
nised with viable virus without adjuvant (1B) showed intermediate
plasma s/p values (medians of 0.15–0.30; ranges 0.41–1.57) at all
time points in the study, with one animal in this group having
higher s/p values (1.7 plasma; 0.27 NS) at d14 than the rest of
group 1B (Supplementary Data, Table 2). In this group, there also
appeared to be no clear response to the booster immunisation at
d28 (Fig. 2A, B). By T-test, group 1B values were not significantly
different from the group 1A values at any timepoint in the plasma
ELISA dataset (Fig. 2A; p > 0.08), but NS ELISA s/p values were sig-
nificantly higher in group 1A at d47, d56 (p < 0.01) and d69
(p < 0.05; Fig. 2B).
Analysis of the VNA titres for both plasma and NS at d0 showed
no background of AlHV-1 neutralising activity, as expected, while
d69 samples showed a similar pattern to the ELISA data, with the
lowest values in group 1C (only one animal had a detectable VNA
titre of 3), intermediate values in group 1B (plasma median titre
68, range 32–90; NS median 6, range <2–8) and highest values in
group 1A (plasma median 512, range 360–2048; NS median 39,
range 11–90; Fig. 2C). The group 1B VNA titres were significantly
lower than group 1A for both plasma and NS, with about ten-fold
lower geometric mean titre (p < 0.0005, T-test; p < 0.01, Mann-
Whitney U test).
Real-time PCR analysis, of DNA samples prepared from blood
buffy coat cells, showed no detection of AlHV-1 DNA in the circu-
lation of immunised animals at any time point during this trial,
while genomic b-actin was detected in all samples.
3.3. Study 2: induction of immune responses by MCF vaccine
containing inactivated virus
Having observed that the attenuated AlHV-1 with adjuvant
induced higher neutralising antibody responses compared to
attenuated AlHV-1 alone, and that storage of the vaccine virus in
the presence of Emulsigen led to >99.9% loss of viability after
1 month, we investigated whether virus viability was important
for the induction of virus neutralising antibodies. The results of
ELISA and VNA on samples from d0 and d56 are summarised in
Fig. 3 and presented in Supplementary Data, Table 3. These show
that in the presence of adjuvant both the viable (group 2A) and
inactivated (group 2B) formulations of the MCF vaccine induced
virus-specific and virus neutralising antibodies in the cattle at
d56 (four weeks after second immunisation). Group 2A plasma
had median s/p 0.51 (range 0.10–0.70) and median VNA titre 360
(range 90–720); while NS had median s/p 0.42 (range 0.16–0.61)
and median VNA titre 45 (range 3–90). One animal in group A
was withdrawn from the study before the second immunisation
for welfare reasons. Group 2B plasma had median s/p 0.38 (range
0.14–0.72) and median VNA titre 122 (range 45–720); while NS
had median s/p 0.32 (range 0.10–0.59) and median VNA titre 17
(range <2–180) (Fig. 3). The antibody responses in the viable (2A)
and inactivated (2B) vaccine groups, analysed by T-Tests of the
s/p values and log2 transformed VNA titres, showed no significant
difference between the responses of groups 2A and 2B. Analysis of
the untransformed data by non-parametric Mann-Whitney U test
gave the same outcome.
In contrast, the culturemediumplus adjuvant control group (2C)
showed no AlHV-1 specific response (plasma and NS s/p val-
ues < 0.06; VNA titres < 2 in all samples). Groups 2A and 2B both
Fig. 3. Study 2; ELISA and VNA data. In each panel, the respective values for each
animal were plotted by sample type and immunisation group as follows: group 2A,
viable AlHV-1 vaccine (mixed with 20% Emulsigen on the day of immunisation);
group 2B, inactivated AlHV-1 vaccine (mixed with 20% Emulsigen 28 days before
immunisation); group 2C, medium plus 20% Emulsigen adjuvant control. Samples
with identical/overlapping values in the same group were plotted offset to each
other. Values from d0 samples were essentially zero or undetectable in all samples
and therefore were not included. (A) d56 ELISA s/p values in blood plasma (plasma
ELISA, dark grey circles) and nasal secretions (NS ELISA, light grey circles); (B) d56
VNA titres in blood plasma (plasma VNA; dark grey circles) and nasal secretions (NS
VNA; light grey circles), plotted on a log2 scale.
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antibody responses at d56, when compared with group 2C, in both
VNAand ELISAwith p < 0.005 in T-tests of plasmaandNS antibodies.
As in study 1, real-time PCR analysis showed that no AlHV-1
DNA was detected in blood samples from study 2 animals at any
time point, while genomic b-actin was detected in all samples.4. Discussion
The current vaccine strategy for use of the live attenuated MCF
vaccine involves the transport of viable virus and Emulsigen adju-
vant (with cold chain) to the study site; the mixing of aliquots of
vaccine virus with the appropriate volume of Emulsigen to make
a 20% (v/v) final emulsion; and the administration of the mixed
vaccine to cattle without undue delay. While this approach has
been used successfully in multiple trials in field locations
[4,20,26], it does not represent an ideal method for deployment
of a commercial vaccine. Understanding the factors involved in
maintaining the efficacy of this vaccine while simplifying its
deployment is therefore of great importance. As a live attenuated
vaccine formulated with adjuvant, the current MCF vaccine is unu-
sual. Few commercial live vaccines require adjuvant but examples
of live-in-oil vaccines have been reported for Newcastle Disease
[28–30]. To improve our understanding of the MCF vaccine, we5
have analysed the viability of attenuated AlHV-1, when stored in
the presence or absence of adjuvant, and performed immunisation
studies focused on two areas: the requirement for adjuvant and the
requirement for viable AlHV-1 in the vaccine formulation.
Initial work showed that the viability of AlHV-1 stored in the
presence of the oil-in-water adjuvant Emulsigen was progressively
reduced at either 4 C or 20 C, such that more than 99.9% viability
was lost after 1 month and no viable virus could be detected after
2 months. The oil-in-water adjuvant Emulsigen could have reduced
virus viability by extraction of the viral envelope and associated
membrane proteins into the oil phase. The progressive nature of
the loss of viability observed in the presence of Emulsigen
(Fig. 1) suggests that this process is slow under the conditions used
– storage at the specified temperature with daily mixing. Addition-
ally, it was observed that the vaccine aliquots separated into aque-
ous and emulsion phases if left undisturbed, suggesting that loss of
viability might be accelerated by continuous mixing.
In study 1, the virus-specific antibody data (ELISA) suggested
that immunisation with viable AlHV-1 in the absence of adjuvant
(group 1B) was associated with a change in the dynamics of plasma
antibody responses (Fig. 2A) and significantly lower nasal secretion
antibody responses (Fig. 2B) after the second immunisation. In
addition, the results showed that group 1B animals had signifi-
cantly lower plasma and NS VNA titres at day 69 post-
immunisation than group 1A animals, which received the AlHV-1
vaccine containing Emulsigen. These observations suggest that
although attenuated viable AlHV-1 can induce a virus-
neutralising immune response in the absence of adjuvant, the mag-
nitude of this antibody response is significantly enhanced by for-
mulation with adjuvant. This is consistent with studies of
Newcastle Disease Virus vaccines, whose immunogenicity could
be potentiated by formulation with oil adjuvants [30,29]. Thus,
there may be a qualitative and quantitative difference in the
immune responses induced in the presence or absence of adjuvant,
with the virus-only immunisation leading to a reduced virus neu-
tralising antibody response that may be less protective. The pres-
ence of adjuvant may lead to a depot effect, concentrating the
virus near the site of injection and facilitating its slow release
and prolonged delivery to local lymph nodes by antigen-
presenting cells. In the absence of adjuvant, the virus may be dis-
tributed rapidly via the circulation and cleared by immune cells
resulting is a less prolonged stimulation. A reduced local and/or
reduced prolonged response in the absence of adjuvant may
explain the reduction in both virus-specific and virus-
neutralising antibodies in nasal secretion samples of group 1B.
The apparent lack of replication of attenuated AlHV-1 in vaccinated
cattle may explain its inability to induce high levels of neutralising
antibodies and generate an effective anamnestic response in the
absence of the depot effect conferred by adjuvant.
In study 2, we compared the AlHV-1 vaccine containing Emulsi-
gen, prepared and used while virus viability was high, with the
same vaccine formulation after storage had reduced virus viability
by >99.9%. The antibody responses in the respective groups at d56
showed that both MCF vaccine formulations induced virus-specific
and virus-neutralising antibody responses of similar magnitude,
while the control group had no virus-specific response (Fig. 3). This
supports the view that viable AlHV-1 is not required for induction
of optimal virus-specific or virus neutralising antibody responses
following vaccination when combined with Emulsigen. The induc-
tion of a reduced virus neutralising immune response following
immunisation by attenuated AlHV-1 without adjuvant, and the
lack of detection of AlHV-1 in the blood samples taken during both
studies, support the view that the vaccine acts as a source of anti-
gen and that significant virus replication or persistence of viable
virus is not required for the development of neutralising antibody
responses in the bovine host.
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AlHV-1 were reported in 1975 and 1980 [22,31]. These publica-
tions described the use of AlHV-1 strains WC11 (non-pathogenic)
or C500 (pathogenic) in live or inactivated vaccines inoculated into
cattle or rabbits with Freund’s complete or incomplete adjuvants.
In each case, circulating virus-neutralising antibody responses
were detected over several months in vaccinated cattle, with titres
in excess of 100. However, protection from MCF, using intravenous
challenge or field exposure to virus, was not demonstrated in cat-
tle. We previously observed that the attenuated MCF virus vaccine
induced protection against a challenge by intranasal inoculation of
cell-free pathogenic AlHV-1, whilst intravenous challenge was fatal
[19]. The induction of virus neutralising antibodies by earlier vac-
cine formulations was demonstrated only within blood samples so
it cannot be determined whether mucosal antibody responses had
been induced. However, these studies suggest that chemically-
inactivated AlHV-1, with appropriate adjuvants, might also induce
protective mucosal virus-neutralising antibody responses.
We have shown that protection from MCF may be associated
with the induction of virus-neutralising antibodies in the mucous
secretions of immunised animals [19–21,25]. The results described
here, that vaccination with attenuated AlHV-1 without adjuvant
elicited a significantly lower titre of virus-neutralising antibodies
than the equivalent adjuvanted vaccine, and that MCF vaccine con-
taining inactivated AlHV-1 induced similar antibody responses to
the vaccine containing viable virus, suggest that while the current
formulation of the MCF vaccine mixes viable virus suspension with
Emulsigen adjuvant just before use, other formulations containing
adjuvant and non-viable AlHV-1 may also elicit a protective
response.
This speculation agrees with previous work [32], in which vac-
cination of rabbits with DNA encoding the OvHV-2 gB, gH and gL
glycoproteins induced virus neutralising antibodies and appeared
to protect the rabbits from intranasal challenge with OvHV-2,
demonstrating protection by appropriately presented viral anti-
gens. However, it will be important to investigate the efficacy of
vaccine formulations that contain inactivated AlHV-1 or which lack
adjuvant. Indeed, the poor mucosal response seen in the virus-only
group of study 1 (group 1B, Fig. 2B) might be improved by mucosal
inoculation of attenuated AlHV-1. Previous work, boosting by the
intranasal route in combination with mucosal adjuvants, induced
moderate titres of virus-neutralising antibodies and demonstrated
some protection from challenge, while VNA titres following vacci-
nation with formalin-inactivated virus were low [19], suggesting
that these areas require further research. This work therefore rep-
resents progress towards the development of a commercial vaccine
for WA-MCF, especially if both virus inactivation and freeze-drying
do not reduce efficacy, and may help facilitate the distribution of
vaccine to at-risk cattle herds by removing the need for an exten-
sive cold-chain.5. Animal welfare
All animal experiments were performed with the approval of
the Moredun Research Institute’s Animal Welfare and Ethical
Review Body (AWERB) in compliance with the UK ‘‘Animals (Scien-
tific Procedures) Act 1986”, with a maximum severity limit of mild.CRediT authorship contribution statement
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